Oryzon Genomics S.A. (LON:0RDB)
London
· Delayed Price · Currency is GBP · Price in EUR 2.735
0.00 (0.00%)
At close: Apr 17, 2025
Oryzon Genomics Revenue
In the year 2024, Oryzon Genomics had annual revenue of 7.36M EUR, down -48.15%. Oryzon Genomics had revenue of 7.36M in the quarter ending December 31, 2024, a decrease of -48.15%.
Revenue
7.36M EUR
Revenue Growth
-48.15%
P/S Ratio
28.45
Revenue / Employee
156.57K EUR
Employees
47
Market Cap
173.14M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.36M | -6.83M | -48.15% |
| Dec 31, 2023 | 14.19M | -1.51M | -9.60% |
| Dec 31, 2022 | 15.70M | 5.08M | 47.88% |
| Dec 31, 2021 | 10.62M | 1.09M | 11.49% |
| Dec 31, 2020 | 9.52M | -756.51K | -7.36% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 42.56B |
| GSK plc | 31.38B |
| Haleon | 11.23B |
| Smith & Nephew | 4.64B |
| ConvaTec Group | 1.83B |
| Hikma Pharmaceuticals | 2.50B |
| HUTCHMED (China) | 503.39M |
| Genus | 671.60M |